---
title: "Tremfya (guselkumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Tremfya (guselkumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Tremfya work (mechanism of action)? Does Tremfya bind to CD64? How is Tremfya metabolized? How quickly does Tremfya reach peak levels after injection? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab), all indications: Pharmacology questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)

## Mechanism

<a id="tremfya-mechanism"></a>

### How does Tremfya work (mechanism of action)?

> “Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 
> subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. 
> IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and 
> immune responses. Guselkumab inhibits the release of proinflammatory cytokines 
> and chemokines.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

> “Interaction between IL-23 and its receptor drives the differentiation, proliferation, and survival of Th17 cells”

Source: [TREMFYA: MOA: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/mechanism-of-action/#moa:~:text=Interaction%20between%20IL%2D23%20and%20its,and%20survival%20of%20Th17%20cells)

On the page, select: MOA

<a id="tremfya-cd64-binding"></a>

### Does Tremfya bind to CD64?

> “Blocking IL-23, a cytokine responsible for inflammation 
> Binding to CD64, a receptor on cells that produce IL-23
> The clinical significance of these findings is unknown.”

Source: [TREMFYA: MOA: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/mechanism-of-action/#:~:text=Blocking%20IL%2D23%2C%20a%20cytokine%20responsible,of%20these%20findings%20is%20unknown.)

> “Findings for dual-acting are limited to in vitro studies that demonstrated guselkumab's binding to CD64 in an inflammatory monocyte model.”

Source: [TREMFYA: MOA: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/mechanism-of-action/#:~:text=Findings%20for%20dual%2Dacting%20are%20limited,in%20an%20inflammatory%20monocyte%20model.)

## Pharmacokinetics

<a id="tremfya-metabolism"></a>

### How is Tremfya metabolized?

> “The exact pathway through which guselkumab is metabolized has not been 
> characterized. As a human IgG monoclonal antibody, guselkumab is expected to 
> be degraded into small peptides and amino acids via catabolic pathways in the 
> same manner as endogenous IgG.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

<a id="tremfya-absorption"></a>

### How quickly does Tremfya reach peak levels after injection?

> “Following a single 100 mg subcutaneous injection in healthy adult subjects, guselkumab 
> reached a mean (± SD) maximum serum concentration of 8.09 ± 3.68 mcg/mL 
> by approximately 5.5 days post dose. The absolute bioavailability of guselkumab 
> following a single 100 mg subcutaneous injection was estimated to be approximately 
> 49% in healthy adult subjects.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Components

<a id="tremfya-inactive-ingredients"></a>

### What are the inactive ingredients in Tremfya?

> “TREMFYA<sup>®</sup> (guselkumab) injection is a sterile, preservative free, clear, and 
> colorless to light yellow solution.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

> “Each TREMFYA 1 mL prefilled syringe, prefilled pen (TREMFYA PEN), or 
> One-Press patient-controlled injector delivers 100 mg guselkumab, 
> L-histidine (0.6 mg), L-histidine monohydrochloride monohydrate (1.5 mg), 
> polysorbate 80 (0.5 mg), sucrose (79 mg) and water for injection at pH 5.8.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Related pages
- [Medical information: Tremfya (guselkumab): All indications](https://www.evicenter.com/medical-information/tremfya)
- [Indication](https://www.evicenter.com/medical-information/tremfya/indication)
- [Safety](https://www.evicenter.com/medical-information/tremfya/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/tremfya/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/tremfya/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya/access-and-coverage)
